隶属于 jopo gmbh
相关临床试验
30
15 进行中
药物批准
10
批准总数
监管机构
2
监管机构数
成立时间
1933
进行中（未招募）
15
50.0%
已完成
11
36.7%
招募中
3
10.0%
终止
1
3.3%
- A ten-week randomized trial found dronabinol, a cannabis-derived THC medication, reduced PTSD nightmare scores by 3.66 points versus 2.17 for placebo, a statistically significant difference. - Complete nightmare remission was achieved in 36.8% of patients on dronabinol compared to 14.5% on placebo, with 57.9% seeing scores at least halved. - Sleep quality improved significantly, though clinician-rated overall PTSD severity and depression scores did not shift, suggesting a nightmare-specific benefit. - Side effects were mostly mild to moderate, with dizziness, increased appetite, and dry mouth most common; no severe adverse events were attributed to the drug.
- A real-world evidence study of 3,546 women across Germany, Austria, and Poland found that only 4.6% received a dysmenorrhea diagnosis despite 88.5% reporting severe menstrual pain levels of 6/10 or higher. - Digital patient outreach campaigns demonstrated 94.6% specificity in identifying women with dysmenorrhea symptoms, suggesting direct-to-patient strategies can effectively reach underdiagnosed populations missed by traditional healthcare settings. - The study revealed that 90.3% of affected women had not sought medical advice or had their symptoms unrecognized as pathological, with nearly half of diagnosed cases receiving only a PMS label rather than proper dysmenorrhea recognition.
